Monday 30 September 2013

NGC Update Service: September 30, 2013

National Guideline Clearinghouse (NGC)

September 30, 2013


New This Week

Guideline Summaries

American College of Chest Physicians

Canadian Agency for Drugs and Technologies in Health

Canadian Task Force on Preventive Health Care

Catalan Agency for Health Information, Assessment and Quality

Centers for Disease Control and Prevention

College of Family Physicians of Canada New Developer

National Collaborating Centre for Mental Health

National Institute for Health and Care Excellence (NICE)

National Kidney Foundation

U.S. Preventive Services Task Force

Announcements

Annotated Bibliographies Feature

NGC will be retiring the Annotated Bibliographies. This feature will no longer be available after October 9th.

NGC Spotlight

See the updated Mobile Device Resources page for information on the availability of full-text guidelines and/or companion documents available in downloadable versions for smart phones and hand-held devices.

Revised Inclusion Criteria

NGC has revised its Inclusion Criteria! Visit our updated Inclusion Criteria page to see the new criteria and send us your comments.

Health Awareness Topics - October 2013

Conference News

  • The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.

U.S. Food and Drug Administration (FDA) Advisories

  • September 27, 2013: Tygacil (tigecycline): FDA notified health professionals and their medical care organizations of a new Boxed Warning describing an increased risk of death when intravenous Tygacil is used for FDA-approved uses as well as for non-approved uses. These changes to the Tygacil Prescribing Information are based on an additional analysis that was conducted for FDA-approved uses after FDA issuing a Drug Safety Communication about this safety concern in September 2010.
  • September 25, 2013: Arzerra (ofatumumab) and Rituxan (rituximab): FDA approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed Warning information about the risk of reactivation of hepatitis B virus (HBV) infection. The revised labels also will include additional recommendations for screening, monitoring, and managing patients on these drugs to decrease this risk.

NGC's Sister Resources


This email was sent to buzzhairs.health@blogger.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364 

No comments:

Post a Comment